Using a breathing device to track COPD treatment with inhaled steroids
Tests whether an oscillometer can measure inhaled steroid effects in adults with COPD flare-ups.
Plain-language title generated from the registry record
Registry title: Oscillometry in the COPD Exacerbator Phenotype With Triple Inhaled Therapy Study
Key facts
- Where
- L'Hospitalet de Llobregat, SpainSee the site
Where in Spain
- Hospital Universitari de BellvitgeL'Hospitalet de Llobregat, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Universitari de Bellvitge
- Trial code
- NCT06931899
- Record updated
- 17 April 2025
- Original description
The objective of this observational study is to determine the effectiveness of inhaled corticosteroids in patients with chronic obstructive pulmonary disease (COPD) and frequent worsening of their respiratory symptoms by using a device called an oscillometer. This instrument is capable of measuring bronchial obstruction and air trapping in the lungs through vibrations during normal breathing. The main question it seeks to answer is:Read full original descriptionShow less
Usefulness of Oscillometry in Assessing the Effectiveness of Inhaled Corticosteroides in Patients With COPD Exacerbator Phenotype
The objective of this observational study is to determine the effectiveness of inhaled corticosteroids in patients with chronic obstructive pulmonary disease (COPD) and frequent worsening of their respiratory symptoms by using a device called an oscillometer. This instrument is capable of measuring bronchial obstruction and air trapping in the lungs through vibrations during normal breathing. The main question it seeks to answer is:
Could oscillometry be useful in assessing the effectiveness of inhaled corticosteroids in patients with COPD exacerbations, in terms of bronchial obstruction and air trapping in the lungs? Patients who choose to participate will undergo oscillometry testing and complete standard COPD questionnaires during three follow-up visits spread over three months.
Inclusion: Age over 18 years; Diagnosis of COPD; Severe-moderate COPD measured by FEV1 and stable; Patient receiving dual bronchodilation therapy (LABA/LAMA) for at least the last 4 months prior to study inclusion and meeting clinical criteria to begin triple inhaled therapy; COPD exacerbations (COPD exacerbations); Blood eosinophils >100 cells/mL in prior laboratory tests; Patient agrees to participate in the study and signs the informed consent form.
Exclusion: COPD in the last 4 weeks, with use of antibiotics or systemic corticosteroids; Previous treatment with ICS in the last 4 months; Chronic lung disease other than COPD; Severe heart failure, with frequent decompensation (in cases of mild decompensation or onset without severe heart disease, do not include the patient within 3 months of decompensation); Severe renal failure; Positive COVID-19 test (do not include until 3 months after diagnosis by ART or COVID-19 PCR); ALT greater than 2.5 times the upper limit of normal. 6. Poorly controlled insulin-dependent diabetes or involvement of 1 or more organs; Active neoplastic processes.